Market Overview - The medical services sector experienced a decline of 2.91% on October 13, with Haoyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - Notable gainers in the medical services sector included: - Meinian Health: closed at 5.29, up 3.52% with a trading volume of 2.2848 million shares [1] - ST Biological: closed at 9.15, up 2.69% with a trading volume of 23,400 shares [1] - International Medical: closed at 4.98, up 2.26% with a trading volume of 356,400 shares [1] - Major decliners included: - Haoyuan Pharmaceutical: closed at 75.50, down 6.79% with a trading volume of 75,700 shares [2] - Boteng Co.: closed at 23.34, down 6.27% with a trading volume of 224,900 shares [2] - Kailaiying: closed at 105.42, down 5.04% with a trading volume of 57,800 shares [2] Capital Flow - The medical services sector saw a net outflow of 870 million yuan from institutional investors, while retail investors contributed a net inflow of 601 million yuan [2][3] - Key stocks with significant capital flow included: - Sanbo Brain Science: net inflow of 21.51 million yuan from institutional investors [3] - International Medical: net inflow of 20.51 million yuan from institutional investors [3] - Jiuzhou Pharmaceutical: net inflow of 10.59 million yuan from institutional investors [3]

博腾股份表示，2025年前三季度，随着公司客户管线、产品管线的不断丰富和拓展，研发技术能力和产 品交付能力的不断提升，公司面向国内及国际市场的总体业务均实现了平稳增长，公司预计实现营业收 入24.8亿元至25.8亿元，同比增长17%至21%。受益于公司营业收入增长，规模化效应显现，公司盈利 能力恢复性提升。此外，公司持续落地降本增效和精益运营举措，运营效率提升，公司整体毛利率同比 持续改善。 北京商报讯（记者 丁宁）10月13日晚间，博腾股份（300363）发布2025年前三季度业绩预告显示，公 司预计前三季度实现归属净利润7320万元至8820万元，同比扭亏为盈。 ...

Company Announcements - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau due to undisclosed non-operating fund occupation by related parties, amounting to 8.9485 million yuan, which has been fully repaid [2] - Aosheng Electronics reported that revenue from controllable nuclear fusion-related products will account for less than 1% of its main business revenue in the first half of 2025 [2] - Yiyi Co. is planning to acquire a pet food company, leading to a stock suspension [3] - Sanmei Co. expects a net profit increase of 172%-193% year-on-year for the first three quarters, driven by a significant rise in the average price of fluorinated refrigerants [4] - Feirongda anticipates a net profit increase of 111%-130% year-on-year for the first three quarters, with growth in AI server cooling-related business revenue [4] - Zhongshi Technology expects a net profit increase of 74%-104% year-on-year for the first three quarters, benefiting from increased shipments of thermal materials and components [4] - Juxin Technology forecasts a net profit increase of 113% year-on-year for the first three quarters, with sales revenue from edge AI processor chips increasing significantly [4] - Chuangjiang New Materials expects a staggering net profit increase of 2058%-2243% year-on-year for the first three quarters [4] - New China Life Insurance anticipates a net profit increase of 45%-65% year-on-year for the first three quarters [4] Investment & Contracts - Fostda plans to invest 1 billion yuan in the construction of an intelligent manufacturing project for marine engineering and equipment [11] Shareholding Changes - Dongxin Co. has set an initial transfer price of 82.5 yuan per share for its inquiry transfer, which is a 16% discount from the closing price [11] - China Jushi has obtained a commitment letter for a stock repurchase loan of up to 630 million yuan [12] - Tianji Co. has reduced its holdings by 2.9996% of the company's shares and has terminated its reduction plan early [3] Performance & Operations - Yingweike reported a net profit of 183 million yuan for the third quarter, an increase of 8.35% year-on-year [13] - Chenguang Biological expects a net profit increase of 344%-402% year-on-year for the first three quarters [14] - Meili Ecology's subsidiary won a bid for a 2.375 billion yuan urban renewal project in Shenzhen [18] Stock Price Movements - Hezhu Intelligent has not generated any revenue related to nuclear fusion concepts [19] - Jinli Yongci confirmed that its recent stock price fluctuations are not due to undisclosed significant matters [20] Other Developments - Heng Rui Medicine's subsidiary received approval for clinical trials of SHR-1905 injection [24] - Renfu Medicine received a drug registration certificate for Dapoxetine Hydrochloride Tablets, which are expected to generate approximately 1.1 billion yuan in sales in 2024 [26]

格隆汇10月13日丨博腾股份(300363.SZ)发布2025年前三季度业绩预告，预计归属于上市公司股东的净 利润为7,320万元至8,820万元，同比扭亏为盈。报告期内，公司客户管线和产品管线持续拓展，研发技 术与交付能力提升，国内外业务平稳增长，营业收入同比增长17%-21%，规模化效应显现，叠加降本增 效和精益运营推进，毛利率持续改善，盈利能力恢复性提升。 ...

Group 1 - The company expects a net profit attributable to shareholders of 73.2 million to 88.2 million yuan for the first three quarters, marking a turnaround from losses in the previous year [1] - The net profit excluding non-recurring gains and losses is projected to be between 50 million and 65 million yuan, also indicating a recovery from losses year-on-year [1] - The company anticipates total operating revenue of 2.48 to 2.58 billion yuan, representing a year-on-year growth of 17% to 21% [1] Group 2 - The growth in revenue is attributed to the continuous expansion of the company's client and product pipelines, as well as improvements in research and development capabilities and product delivery [1] - The company has implemented cost reduction and efficiency enhancement measures, leading to improved operational efficiency and a continuous increase in overall gross margin year-on-year [1]

每经AI快讯，10月13日，博腾股份(300363.SZ)公告称，博腾股份发布2025年前三季度业绩预告，预计 归属于上市公司股东的净利润为7,320万元至8,820万元，同比扭亏为盈。报告期内，公司客户管线和产 品管线持续拓展，研发技术与交付能力提升，国内外业务平稳增长，营业收入同比增长17%-21%，规模 化效应显现，叠加降本增效和精益运营推进，毛利率持续改善，盈利能力恢复性提升。 ...

Profit Forecast - The company expects a net profit attributable to shareholders of between 73.20 million and 88.20 million yuan, a turnaround from a loss of 206.43 million yuan in the same period last year [4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 50.00 million and 65.00 million yuan, compared to a loss of 213.50 million yuan in the previous year [4]. - Non-recurring gains and losses are expected to impact net profit by approximately 23.20 million yuan, compared to 7.07 million yuan in the same period last year [4]. Revenue Growth - The company anticipates total operating revenue of 2.48 billion to 2.58 billion yuan, representing a year-on-year growth of 17% to 21% [6]. - The company has seen a recovery in profitability due to revenue growth and the realization of scale effects [7]. Operational Efficiency - Continuous implementation of cost reduction and efficiency enhancement measures has improved overall operational efficiency and gross margin [7].

Core Viewpoint - The Biotech Index (970038) closed at 2325.47 points, down 1.85%, with a trading volume of 31.496 billion yuan and a turnover rate of 2.07% [1] Group 1: Index Performance - On the day, 6 out of the index's constituent stocks rose, with Huace Testing leading with a 2.51% increase, while 44 stocks declined, with Boteng Co. leading the decline at 6.27% [1] - The top ten constituent stocks of the Biotech Index are primarily in the pharmaceutical and biotechnology sectors, with notable declines in major stocks like Mindray Medical and Changchun High-tech [1] Group 2: Stock Details - The top ten constituent stocks by weight include: - Mindray Medical (13.81% weight) at 235.20 yuan, down 2.81%, with a market cap of 285.166 billion yuan [1] - Changchun High-tech (5.41% weight) at 132.06 yuan, down 3.11%, with a market cap of 53.872 billion yuan [1] - Kanglong Chemical (4.66% weight) at 31.76 yuan, down 3.99%, with a market cap of 56.475 billion yuan [1] - Other notable stocks include Taige Pharmaceutical and Aimeike, both showing declines [1] Group 3: Capital Flow - The Biotech Index constituent stocks experienced a net outflow of 722 million yuan from main funds, while retail investors saw a net inflow of 534 million yuan [3] - Specific stocks like Mindray Medical and Changchun High-tech had varying levels of net inflow and outflow from different investor categories, indicating mixed investor sentiment [3]

Core Insights - The company, Boten Co., reported that as of September 19, 2025, the total number of shareholders (including both regular accounts and margin trading accounts) is 51,542 [1] Summary by Categories - **Shareholder Information** - The total number of shareholders is 51,542 as of the specified date [1]

Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]